Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma

NCT02428192 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

NIH

Sponsor class

Conditions

Metastatic Leiomyosarcoma
Unresectable Leiomyosarcoma
Uterine Corpus Leiomyosarcoma

Interventions

BIOLOGICAL: Ipilimumab
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Nivolumab

Sponsor

National Cancer Institute (NCI)